Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome

INTRODUCTION: Alport syndrome is a rare genetic disorder that affects as many as 60,000 persons in the USA and a total of 103,000 persons (<5 per 10,000) in the European Union [1, 2]. It is the second most common inherited cause of kidney failure and is characterized by progressive loss of kidney...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Nephrol
Autors principals: Chertow, Glenn M., Appel, Gerald B., Andreoli, Sharon, Bangalore, Sripal, Block, Geoffrey A., Chapman, Arlene B., Chin, Melanie P., Gibson, Keisha L., Goldsberry, Angie, Iijima, Kazumoto, Inker, Lesley A., Knebelmann, Bertrand, Mariani, Laura H., Meyer, Colin J., Nozu, Kandai, O'Grady, Megan, Silva, Arnold L., Stenvinkel, Peter, Torra, Roser, Warady, Bradley A., Pergola, Pablo E.
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2021
Matèries:
Patient-Oriented, Translational Research: Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8220919/
https://ncbi.nlm.nih.gov/pubmed/33789284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000513777
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars